Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q3 2022 Earnings Presentation
16 slides from Bonesupport Holding Ab's earnings presentation, Oct 27, 2022
Slide 1: Q3 (2022) Report
BONESUPPORT Q3 (2022) Report October 27th , 2022 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: BONESUPPORT – Third quarter report 2022
BONESUPPORT – Third quarter report 2022 Q3 2022: • Net sales SEK 84,6 m, growth: +54% versus Q3 2021, (+39% in constant exchange rates, CER) • Operating result (before incentive provisions): -4,4 mSEK (-15,7 mSEK): a SEK 11.3 m operating result improvement • Reported EBIT: SEK -13,9 m • Launch prepa
Slide 4: Q3 2022: Nine consecutive all-time-highs and acceleration in growth rates
Q3 2022: Nine consecutive all-time-highs and acceleration in growth rates LTM Quarterly Sales per Segment 300 287 300 Rapidly expanding customer base and broadened use of CERAMENT 275 257 275 250 234 250 225 213 225 205 197 200 180181 200 173 Pandemic influence and staff Net Sales, SEK m Net Sales,
Slide 5: North America: Strong market share gains and expansion of customer base
North America: Strong market share gains and expansion of customer base Q3 2022 • Sales of SEK 56,3m, growth of 72% over Q3 2021, growth of 49% in constant exchange rate, CER • Sales in Q3 2022 represented a reported sequential growth of 24% over Q2 2022 Expanding customer base • Solid customer recr
Slide 6: North America: Market dynamics
North America: Market dynamics CERAMENT G launch in the U.S. • Listing with app. 4/10 of customer base on contracts • Approvals from GPOs (Premier, Healthtrust) and several major hospital systems • Launch has started. Account by account…Surgeon by surgeon • Strong interest, from existing and new cus
Slide 7: EUROW: Continued growth momentum
EUROW Continued growth momentum. Impact from healthcare staff shortages still present Q3 2022 • Sales of SEK 28,3 m, growth of 28% vs Q3 2021, +23% in constant exchange rates, CER • Some recovery in procedure, despite impact from pandemic at onset of quarter and operating room staff challenges • Man
Slide 8: Long term data on CERAMENT G in bone infection
Long term data on CERAMENT G in bone infection McNally et al. ‘Mid- to long-term results of single-stage surgery for patients with chronic osteomyelitis using a bioabsorbable gentamicin-loaded ceramic carrier.’ Bone Joint J. 2022;104-B(9):1095-1100. 100 Prospective case series study on patients with
Slide 9: Financial Report
BONESUPPORT Q3 (2022) Report Financial Report
Slide 10: Q3 2022 net sales SEK 84.6 m
Q3 2022 net sales SEK 84.6 m SEK m • 72 percent reported growth in NA. 49 percent growth in CER • 28 percent reported growth in EUROW. 23 percent growth CER • High impact from currency movements 10
Slide 11: North America and EUROW net sales and gross margin
North America +72% EUROW +28% (+49% CER) (+23% CER) Net sales Net sales Q3-22 Q3-22 North America 2022 2021 EUROW 2022 2021 SEK m Q3-22 Q2-22 Q1-22 Q4-21 Q3-21 SEK m Q3-22 Q2-22 Q1-22 Q4-21 Q3-21 Net Sales 56.3 46.0 41.2 34.8 32.7 Net Sales 28.3 28.6 25.2 26.6 22.2 Gross profit 53.1 42.9 38.6 32.7 3
Slide 12: A 11.3 MSEK profit improvement before long-term incentive provisions
A 11.3 MSEK profit improvement before long-term incentive provisions Key Figures 2022 2021 2020 SEK m Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Net Sales 84.6 74.6 66.3 61.4 54.9 51.8 44.8 53.2 Gross Margin (%) 90.8 89.0 90.5 89.3 89.0 89.5 88.6 89.8 Reported Operating Loss -13.9 -14.9 -16.5 -21.8 -13.3 -25.9 -19.7 -
Slide 13: Q3 expenses grew with market investments and currency impact
Q3 expenses grew with market investments and currency impact Key Figures 2022 2021 2020 SEK m Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Selling expenses (less commissions) 43.0 40.8 37.5 38.5 35.5 34.1 31.2 33.9 Sales Commissions 17.8 14.2 12.9 11.4 10.0 9.3 7.9 8.4 Research and Development expenses 12.6 13.6 12.1 14
Slide 14: Clear Corporate Strategy Driving Value Creation
BONESUPPORT Q3 (2022) Report Clear Corporate Strategy Driving Value Creation
Slide 15: BONESUPPORT entering the next chapter of development
BONESUPPORT entering the next chapter of development • CERAMENT G (Gentamicin) launch in the US T R E AT M E N T P R E F E R E N C E – Only FDA authorized product in category, addressing a market opportunity of USD 780 m – Strong and well-developed US commercial infrastructure (375 sales reps) with
Slide 16: Q&A
BONESUPPORT Q3 (2022) Report Q&A